Skip to main content
SpringerLink
Log in

Prevention and Management of the Adverse Effects Associated with Immunosuppressive Therapy

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Advances in immunosuppressive therapy have resulted in significantly improved patient and graft survival after solid organ transplantation. However, increased use has brought attention to specific toxicities associated with the use of these agents. Corticosteroid therapy can result in a wide array of short and long term toxicities. Management of these effects has focused on alternate day and dosage reduction protocols. Myelosuppression, hepatotoxicity, alopecia and gastrointestinal adverse effects are associated with azathioprine and generally respond to a reduction in dosage or withdrawal. Cyclophosphamide myelosuppression is managed in a similar manner. Use of cyclosporin, while the mainstay of immunosuppressive therapy, is often complicated by several well documented adverse effects. Short and long term nephrotoxicity is often managed through pharmacokinetic dosing strategies as well as pharmacological intervention with calcium channel blockers, prostaglandin analogues, pentoxifylline and thromboxane antagonists. Cyclosporin-induced hypertension, hyperlipidaemia, hyperkalaemia and hyperuricaemia are generally responsive to appropriate dietary restrictions and pharmacological therapies. The adverse effects associated with polyclonal antilymphocyte agents (fever, chills, rash, arthralgias) occur in response to the administration of foreign protein substances but can be prevented by pretreatment with corticosteroids, diphenhydramine and paracetamol (acetaminophen). The administration of muromonab CD3 (OKT3) stimulates the release of cytokines resulting in potentially severe complications seen during the first 1 or 2 doses. Pretreatment with diphenhydramine, low dose corticosteroids and paracetamol as well as proper fluid management has reduced the incidence of this syndrome. However, agents such as high dose corticosteroids, indomethacin, pentoxifylline and anti-tumour necrosis factor monoclonal antibodies may further decrease the severity of cytokine-induced toxicity. Antimurine antibodies may also develop during muromonab CD3 therapy, potentially limiting the efficacy of this agent. However, continued concomitant immunosuppressive therapy has significantly reduced antibody formation.

In summary, as newer agents are developed with narrow therapeutic windows, it will be critical to identify specific drug toxicity and to develop preventative and management therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. New England Journal of Medicine 327: 736, 1992a

    PubMed  CAS  Google Scholar 

  • Abramowicz D, Pradier O, Marchant A, Florquin S, De Pauw L, et al. Induction of thrombosis within renal grafts by high-dose prophylactic OKT3. Lancet 339: 777–778, 1992b

    PubMed  CAS  Google Scholar 

  • Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, et al. Release of tumor necrosis factor-alpha, interleukin-2 and interferon-gamma in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47: 606–608, 1989

    PubMed  CAS  Google Scholar 

  • Adams M and the Enisoprost Renal Transplant Study Group. Enisoprost in renal transplantation. Transplantation 53: 338–345, 1992

    PubMed  CAS  Google Scholar 

  • Adler M, Delhaye M, Deprez C, Hardy N, Gelin M, et al. Hepatic vascular disease after kidney transplantation: report of two cases and review of literature. Nephrology Dialysis Transplantation 2: 183–188, 1987

    CAS  Google Scholar 

  • Adu D, Michael J, Turney TM, McMaster P. Hyperkalemia in cyclosporine-treated renal allograft recipients. Lancet 2: 370–372, 1983

    PubMed  CAS  Google Scholar 

  • Alcaraz A, Oppenheimer F, Talbot-Wright R, Fernandez C, Manalich M, et al. Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplantation Proceedings 23: 2383–2384, 1991

    PubMed  CAS  Google Scholar 

  • Alegre M, Depierreux M, Florquin S, Najdovski T, Vandenabeele P, et al. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions. Transplantation Proceedings 22: 1920–1921, 1990

    PubMed  CAS  Google Scholar 

  • Alegre M, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52: 674–679, 1991a

    PubMed  CAS  Google Scholar 

  • Alegre M, Vandenabeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, et al. Cytokine release syndrome induced by the 145–2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. Journal of Immunology 146: 1184–1191, 1991b

    CAS  Google Scholar 

  • Awazu M, Sugiura M, Inagami T, Ichikawa I, Kon V. Cyclosporine promotes glomerular endothelin binding in vivo. Journal of the American Society of Nephrology 1: 1253–1259, 1991

    PubMed  CAS  Google Scholar 

  • Ballantyne C, Podet E, Patsch W, Harati Y, Appel V, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. Journal of the American Medical Association 262: 53–56, 1989

    PubMed  CAS  Google Scholar 

  • Bantle J, Paller M, Boudreau R, Olivari M, Ferris T. Long-term effects of cyclosporine on renal function in organ transplant recipients. Journal of Laboratory and Clinical Medicine 115: 233–240, 1990

    PubMed  CAS  Google Scholar 

  • Berkenboom G, Unger P, Goldman M, Fang Z, Fontaine J. Prevention of cyclosporine A-induced vascular toxicity by pentoxifylline. Journal of Cardiovascular Pharmacology 18: 761–768, 1991

    PubMed  CAS  Google Scholar 

  • Bertani T, Ferrazzi P, Schieppati A, Ruggenenti P, Gamba A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney International 40: 243–250, 1991

    PubMed  CAS  Google Scholar 

  • Bia M, Tyler K. Evidence that calcium channel blockade prevents cyclosporine-induced exacerbation of renal ischemic injury. Transplantation 51: 293–295, 1991

    PubMed  CAS  Google Scholar 

  • Bianco J, Almgren J, Kern D. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 51: 925–927, 1991

    PubMed  CAS  Google Scholar 

  • Bielory L, Gascon P, Lawley TJ, Young NS, Frank MM. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine 67: 40–57, 1988

    PubMed  CAS  Google Scholar 

  • Bielory L, Yancey KB, Young NS, Frank MM, Lawley TJ. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. Journal of the American Academy of Dermatology 13: 411–417, 1985

    PubMed  CAS  Google Scholar 

  • Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. New England Journal of Medicine 324: 370–376, 1991

    PubMed  CAS  Google Scholar 

  • Brooks D, Ohlstein E, Contino L, Storer B, Pullen M, et al. Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. European Journal of Pharmacology 194: 115–117, 1991

    PubMed  CAS  Google Scholar 

  • Brunner L, Vadiei K, Lyer L, Luke D, Iyer L, Luke D. Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. Renal Failure 11: 97–104, 1989

    PubMed  CAS  Google Scholar 

  • Burack D, Griffith B, Thompson M, Kahl L. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. American Journal of Medicine 92: 141–146, 1992

    PubMed  CAS  Google Scholar 

  • Calne RY. Twenty years experience of immunosuppression in organ transplantation. Transplantation Proceedings 14: 91–97, 1982

    Google Scholar 

  • Cerami A, Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunology Today 9: 28–31, 1988

    PubMed  CAS  Google Scholar 

  • Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7: 165–177, 1987

    PubMed  CAS  Google Scholar 

  • Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, et al. In vivo cell activation following OKT3 administration. Transplantation 49: 697–702, 1990

    PubMed  CAS  Google Scholar 

  • Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and inter-feron-α. New England Journal of Medicine 320: 1420–1421, 1989

    PubMed  CAS  Google Scholar 

  • Chatenoud L, Hiesse C, Ferran C, et al. OKT3-induced cytokine-release syndrome: preventive effect of anti-tumour necrosis factor monoclonal antibody. Transplantation Proceedings 25 (Suppl. 1): 47–51, 1993

    PubMed  CAS  Google Scholar 

  • Chatenoud L, Jonker M, Villeman F, Goldstein G, Bach JF. The human immune response to OKT3 is oligoclonal. Science 732: 1406–1408, 1986

    Google Scholar 

  • Chatenoud L, Legendre C, Ferran C, Bach J, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetic prerequisites. Transplantation 51: 334–338, 1991

    PubMed  CAS  Google Scholar 

  • Coffman T, Carr D, Yarger W, Klotman P. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43: 282–285, 1987

    PubMed  CAS  Google Scholar 

  • Coleman AE, Norman DJ. OKT3 encephalopathy. Annals of Neurology 28: 837–838, 1990

    PubMed  CAS  Google Scholar 

  • Cosimi AB. Clinical development of orthoclone OKT3. Transplantation Proceedings 14 (Suppl. 1): 7–16, 1987a

    Google Scholar 

  • Cosimi AB. OKT3: first-dose safety and success. Nephron 46: 12–18, 1987b

    PubMed  Google Scholar 

  • Curtis J, Luke R, Jones P, Diethelm A. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. American Journal of Medicine 85: 134–138, 1988

    PubMed  CAS  Google Scholar 

  • Cusi D, Barlassina C, Niutta E, Elli A, Quarto-diPalo F, et al. Mechanisms of cyclsoporine-induced hypertension. Clinical and Investigative Medicine 14: 607–613, 1991

    PubMed  CAS  Google Scholar 

  • Dawidson I, Rooth P, Fry W, Sandor Z, Willms C, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 48: 575–580, 1989

    PubMed  CAS  Google Scholar 

  • Dawidson I, Rooth P, Lu C, Sagalowsky A, Diller K, et al. Verapamil improves the outcome after cadaver renal transplantation. Journal of the American Society of Nephrology 2: 983–990, 1991

    PubMed  CAS  Google Scholar 

  • Davidson J, Tsakiris D, Briggs J, Junor B. Osteonecrosis and fractures following renal transplantation. Clinical Radiology 35: 27–35, 1985

    Google Scholar 

  • Dean NC, Amend WC, Matthay MA. Adult respiratory distress syndrome related to antilymphocyte globulin therapy. Chest 4: 619–623, 1987

    Google Scholar 

  • Debets JMH, Leunissen KML, Van Hooff HJ, Van Der Linden CJ, Buurman WA. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation 47: 487–492, 1989

    PubMed  CAS  Google Scholar 

  • DeGroen P. Cyclosporine, low-density lipoprotein and cholesterol. Mayo Clinic Proceedings 63: 1012–1021, 1988

    CAS  Google Scholar 

  • DePihno RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver. Gastroenterology 86: 162–165, 1984

    Google Scholar 

  • DeVries CR, Freha FS. Hemorrhagic cystitis: a review. Journal of Urology 143: 1–7, 1990

    PubMed  CAS  Google Scholar 

  • DiPalo F, Elli A, Rivolta R, Parenti M, Palazzi P, et al. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings 23: 969–971, 1991

    Google Scholar 

  • Emmons C, Smith J, Flanigan M. Cerebrospinal fluid inflammation during OKT3 therapy. Lancet 2: 510–511, 1986

    PubMed  CAS  Google Scholar 

  • Feehally J, Walls J, Mistry N, Horsburgh T, Taylor J, et al. Does nifedipine ameliorate cyclosporine A nephrotoxicity?. British Medical Journal 295: 310, 1987

    PubMed  CAS  Google Scholar 

  • Feldhoff C, Goldman AI, Najarian JS, Mauer SM. A comparison of alternative day and daily steroid therapy in children following renal transplantation. International Journal of Pediatric Nephrology 5: 11–14, 1984

    PubMed  CAS  Google Scholar 

  • Ferran C, Bluestone J, Bach J, Chatenoud L. In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody. Transplantation Proceedings 22: 1920–1921, 1990b

    Google Scholar 

  • Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 50: 642–648, 1990a

    PubMed  CAS  Google Scholar 

  • Ferran C, Dy M, Sheehan K, Schreiber R, Grau G, et al. Cascade modulation by anti-tumour necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. European Journal of Immunology 21: 2349–2353, 1991

    PubMed  CAS  Google Scholar 

  • First MR, Alexander JW, Wadhwa N, Penn I, Munda R, et al. The use of low dose cyclosporine, azathioprine and prednisone in renal transplantation. Transplantation Proceedings 18 (Suppl. 1): 132–135, 1986

    PubMed  CAS  Google Scholar 

  • First MR, Schroeder T, Hariharan S, Alexander J, Weiskittel P. The effect of indomethacin on the febrile response following OKT3 therapy. Transplantation 53: 91–94, 1992

    PubMed  CAS  Google Scholar 

  • First MR, Schroeder TJ, Melvin DB, Munda R, Fidler JD, et al. OKT3 therapy in kidney, liver, heart, and pancreas transplantation. Clinical Transplantation 2: 185–189, 1988

    Google Scholar 

  • Frasier LH, Sarathchandra K, Kehrer JP. Cyclophosphamide toxicity: characterising and avoiding the problem. Drugs 42: 781–795, 1991

    Google Scholar 

  • Frei U, Harms A, Bakovic-Alt R, Pichlmayr R, Koch K. Calcium channel blockers for kidney protection. Journal of Cardiovascular Pharmacology 16 (Suppl. 6): S11–S15, 1990

    PubMed  Google Scholar 

  • Gaston R, Deierhoi M, Patterson T, Prasthofer E, Julian BA, et al. OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney International 39: 141–148, 1991

    PubMed  CAS  Google Scholar 

  • Gewurz H, Pickering RJ, Moberg A, Simmons RL, Good RA, et al. Reactivities to horse anti-lymphocyte globulin-serum sickness nephritis with complement alterations in men. International Archives of Allergy and Applied Immunology 39: 210–220, 1970

    PubMed  CAS  Google Scholar 

  • Gladue R, Newborg M. The protective effects of the thromboxane synthetase inhibitor Damzegrel on nephrotoxicity in cyclosporine-treated rats. Transplantation 52: 837–841, 1991

    PubMed  CAS  Google Scholar 

  • Goldberg HK, Wong PY, Cole EH, Levy GA, Skorecki KL. Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effect on intracellular calcium signalling in mesangial cells. Transplantation 47: 731–733, 1989

    PubMed  CAS  Google Scholar 

  • Goldman M, Aleavc M, Deschodt-Lanckman M, Depierreux D, Abramowicz L, et al. The nephrotoxicity of monoclonal anti-CD3 antibodies: clinical and experimental studies. Nephrology Dialysis Transplantation 4: 517–518, 1989

    Google Scholar 

  • Gores P, Fryd D, Sutherland D, Najarian J, Simmons R. Hy-peruricemia after renal transplantation. American Journal of Surgery 156: 397–400, 1988

    PubMed  CAS  Google Scholar 

  • Hardie J, Matsunami C, Hilton A, Dyer J, Rumbach O. Ocular complications in renal transplant recipients. Transplantation Proceedings 24: 177, 1992

    PubMed  CAS  Google Scholar 

  • Hardy MA. Beneficial effects of heterologous antilymphoid globulins in renal transplantation: one believers view. American Journal of Kidney Diseases 2: 79–86, 1982

    PubMed  CAS  Google Scholar 

  • Hariharan S, First MR, Schroeder TJ, Weiskittel, Alexander JW. Prednisone reduction and withdrawal in living related and cadaver renal transplant recipients. Kidney International, in press, 1993

  • Harkiss MD, Brown DL, Cory-Pearce R, English TAH. Serial analysis of circulating immune complexes, complement, and antithymocyte globulin antibodies in heart transplant recipients. Journal of Clinical Immunology 3: 117–126, 1983

    PubMed  CAS  Google Scholar 

  • Heering P, Grabensee B. Influence of cyclosporin A on renal tubular function after kidney transplantation. Nephron 59: 66–70, 1991

    PubMed  CAS  Google Scholar 

  • Hesse CJ, Heyse P, Stolk BJ, Hendriks GF, Weimar W, et al. Difference in antibody formation to OKT3 between kidney and heart recipients. Transplantation Proceedings 21: 979–980, 1989

    PubMed  CAS  Google Scholar 

  • Higgins RM, Ratcliffe PJ. Hypercholesterolemia and vascular disease after transplantation. Transplantation Review 5: 131–140, 1991

    Google Scholar 

  • Horn M, Phebus C, Blatt J. Cancer chemotherapy after solid organ transplantation. Cancer 66: 1468–1471, 1990

    PubMed  CAS  Google Scholar 

  • Horsmans Y, Rahier J, Geubel AP. Reversible cholestasis and bile duct injury following azathioprine therapy: a case report. Liver 11: 89–93, 1991

    PubMed  CAS  Google Scholar 

  • Hricik DE, Mayes JT, Schulak JA. Inhibition of anti-OKT3 antibody generation by cyclosporine-results of prospective randomized trial. Transplantation 50: 237–240, 1990

    PubMed  CAS  Google Scholar 

  • Hricik D, Mayes J, Schulak J. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. American Journal of Kidney Diseases 18: 353–358, 1991

    PubMed  CAS  Google Scholar 

  • Hricik DE, Whalen CC, Lautman J, Bartucci MR, Moir EJ, et al. Withdrawal of steroids after renal transplantation — clinical predictors of outcome. Transplantation 53: 41–45, 1992

    PubMed  CAS  Google Scholar 

  • Ihara H, Hosokawa S, Ogino T, Arima M, Ikoma F. Activation of K+ channel and inhibition of Na+-K+ ATPase of human erythrocytes by cyclosporine: possible role in hyperpotassemia in kidney transplant recipients. Transplantation Proceedings 22: 1736–1739, 1990

    PubMed  CAS  Google Scholar 

  • Jaffers GT, Fuller TC, Cosimi AB, Russell PS, Winn HJ, et al. Monoclonal antibody therapy: Anti-idiotypic and non-antidiotypic antibodies to OKT3 arising despite intense immuno-suppression. Transplantation 41: 572–578, 1986

    PubMed  CAS  Google Scholar 

  • Jarowenko M, Flechner S, Van Buren C, Lorber M, Kahan B. Influence of cyclosporine on posttransplant blood pressure response. American Journal of Kidney Diseases 10: 98–103, 1987

    PubMed  CAS  Google Scholar 

  • Jean G, Cahen R, Barbier Y, Trolliet P, Francois B. Raised serum tumour necrosis factor in delayed antilymphocyte globulin adverse reactions. Nephrology Dialysis Transplantation 7: 559–564, 1992

    CAS  Google Scholar 

  • Jeejeebhoy HF. Heterologous antilymphocyte serum: a review. Canadian Journal of Surgery 14: 5–15, 1971

    CAS  Google Scholar 

  • Kahan BD. Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy, and prognosis. American Journal of Kidney Diseases 8: 323–331, 1986

    PubMed  CAS  Google Scholar 

  • Kahan B. Cyclosporine. New England Journal of Medicine 321: 1725–1738, 1989

    PubMed  CAS  Google Scholar 

  • Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 46: 631–644, 1988

    PubMed  CAS  Google Scholar 

  • Kamel KS, Ethier JH, Quaggin S, Levin A, Albert S, et al. Studies to determine the basis for hyperkalemia in recipients of renal transplants who are treated with cyclosporine. Journal of the American Society of Nephrology 2: 1279–1284, 1992

    PubMed  CAS  Google Scholar 

  • Kasiske BL, Heim-Duthoy K, Ma JZ. Elective cyclosporine withdrawal after renal transplantation: a meta-analysis. Journal of the American Medical Association 269: 395–400, 1993

    PubMed  CAS  Google Scholar 

  • Kasiske B, Tortorice K, Heim-Duthoy K, Awni W, Rao V. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. American Journal of Kidney Diseases 17: 700–707, 1991

    PubMed  CAS  Google Scholar 

  • Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 49: 95–98, 1990

    PubMed  CAS  Google Scholar 

  • Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant patients. Transplantation Proceedings 20: 27–30, 1988

    PubMed  CAS  Google Scholar 

  • Kiberd B. Cyclosporine-induced renal dysfunction in human renal allograft recipients. Transplantation 48: 965–969, 1989

    PubMed  CAS  Google Scholar 

  • Kirkman RL, Strom TB, Weir MR, Tilney NL. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 34: 347–51, 1982

    PubMed  CAS  Google Scholar 

  • Kivisto K. A review of assay methods for cyclosporine: clinical implications. Clinical Pharmacokinetics 23: 173–190, 1992

    PubMed  CAS  Google Scholar 

  • Knight RJ, Vathsala A, Schoenberg L, Camel S, Weinberg RB, et al. Treatment of hyperlipidemia in renal transplant patients with gemflbrozil and dietary modifications. Transplantation 53: 224–225, 1992

    PubMed  CAS  Google Scholar 

  • Kopp J, Klotman P. Cellular and molecular mechanisms of cyclo-sporin nephrotoxicity. Journal of the American Society of Nephrology 1: 162–179, 1990

    PubMed  CAS  Google Scholar 

  • Laskow A, Curtis J. Post-transplant hypertension. American Journal of Hypertension 3: 721–735, 1990

    PubMed  CAS  Google Scholar 

  • Lee C, Logan J, Zukoski C. Cardiovascular collapse following orthoclone OKT3 administration: a case report. American Journal of Kidney Diseases 17: 73–75, 1991

    PubMed  CAS  Google Scholar 

  • Levine LA, Richie JP. Urological complications of cyclophosphamide. Journal of Urology 141: 1063–1069, 1989

    PubMed  CAS  Google Scholar 

  • Lin H, Rocher L, McQuillan A, Schmaltz S, Palella T, et al. Cyclosporine-induced hyperuricemia and gout. New England Journal of Medicine 321: 287–292, 1989

    PubMed  CAS  Google Scholar 

  • Lucas VP, Ponge TD, Plougastel-Lucas ML, Glemain P, Hourmant M, et al. Musculoskeletal pain in renal-transplant recipients. New England Journal of Medicine 325: 1449–1550, 1991

    PubMed  CAS  Google Scholar 

  • Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, et al. Cyclosporine toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335: 11–15, 1990

    PubMed  CAS  Google Scholar 

  • Ludwin D, White N, Tsai S, Orovan W, Smith EKM. Complications related to the route of Minnesota antilymphoblast globulin administration in renal transplant recipients. Transplantation Proceedings 17: 1945–1946, 1985

    PubMed  CAS  Google Scholar 

  • Luke R. Mechanism of cycloporine-induced hypertension. American Journal of Hypertension 4: 468–471, 1991

    PubMed  CAS  Google Scholar 

  • Maddocks JL, Lennard L, Amess J, Amos R, Thomas RM. Azathioprine and severe bone marrow suppression. Lancet 1: 156, 1986

    PubMed  CAS  Google Scholar 

  • Madaio MP, Spiegel JE, Levey AS. Life threatening thrombo-cytopenia complicating antithymocyte globulin therapy for acute kidney transplant rejection. Transplantation 45: 647–649, 1988

    PubMed  CAS  Google Scholar 

  • Margreiter R, Bosmuller C, Spielberger M, Schmidt T, Konigsrainer A. Cyclosporine monotherapy after cadaveric renal transplantation. Transplantation Proceedings 21: 1591, 1989

    PubMed  CAS  Google Scholar 

  • Markell M, Friedman E. Hyperlipidemia after organ transplantation. American Journal of Medicine 87: 51–67N, 1989

    Google Scholar 

  • McManus R, Ohair D, Schwriger J, Beitzinger J, Siegel R. Cyclo-sporine-associated central neurotoxicity after heart transplantation. Annals of Thoracic Surgery 53: 326–327, 1992

    PubMed  CAS  Google Scholar 

  • Mehls O, Tonshoff B. Growth hormone in renal transplantation — the mode of action, animal studies and clinical use. Journal of the American Society of Nephrology 2: S284–S289, 1992

    PubMed  CAS  Google Scholar 

  • Metselaar H, Steenberge E, Bijnen A, Jeekel J, Linge B, et al. Incidence of osteonecrosis after renal transplantation. Acta Or-thopaedica Scandanavica 56: 413–415, 1985

    CAS  Google Scholar 

  • Mier JW, Vachino G, Van Der Meer JWM, Numerof RP, Adams S, et al. Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2 in cancer patients. Journal of Clinical Immunology 8: 426–436, 1988

    PubMed  CAS  Google Scholar 

  • Miller LW, Wolford T, McBride LR, Peigh P, Pennington DG. Successful withdrawal of corticosteroids in heart transplantation. Journal of Heart and Lung Transplantation 11: 431–434, 1992

    PubMed  CAS  Google Scholar 

  • Min DI, Monaco AP. Complications associated with immuno-suppressive therapy and their management. Pharmacotherapy 11: 119S–125S, 1991

    PubMed  CAS  Google Scholar 

  • Mobb G, Shiting P, Feehally J, Veitch P, Bell P. The effect of the thromboxane receptor antagonist GR32191B on cyclosporine-induced nephrotoxicity. Transplantation Proceedings 23: 1241–1243, 1991

    PubMed  CAS  Google Scholar 

  • Monaco AP. Antilymphocyte globulin: a clinical transplantation research opportunity. American Journal of Kidney Diseases 2: 67–78, 1982

    PubMed  CAS  Google Scholar 

  • Morales J, Andres A, Montoyo C, Ortuno B, Rodicio J. Does calcium antagonist improve established early ciclosporin nephrotoxicity after renal transplantation? Nephron 57: 227–229, 1991

    PubMed  CAS  Google Scholar 

  • Moran M, Mozes M, Maddux M, Veremis S, Bartkus C, et al. Prevention of acute graft rejection by the prostaglandin E analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. New England Journal of Medicine 322: 1183–1188, 1990

    PubMed  CAS  Google Scholar 

  • Morozumi K, Thiel G, Albert F, Banfi G, Gudat F, et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clinical Nephrology 38: 1–8, 1992

    PubMed  CAS  Google Scholar 

  • Mowbray JF. The complications of antilymphocyte therapy. Proceedings of the Royal Society of Medicine 63: 1067–1068, 1970

    PubMed  CAS  Google Scholar 

  • Myers B. Cyclosporine nephrotoxicity. Kidney International 30: 964–974, 1986

    PubMed  CAS  Google Scholar 

  • Nelson PW, Jaffers GJ, Fuller TC, Cosimi AB, Colvin RB. Reduction of immune response to OKT3 monclonal antibody. Transplantation Proceedings 17: 644–645, 1985

    Google Scholar 

  • Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function by diltiazem and iloprost. Transplantation Proceedings 21: 1221–1224, 1989

    PubMed  CAS  Google Scholar 

  • Niblack G, Johnson K, Williams T, Green W, Richie R, et al. Antibody formation following administration of antilymphocyte serum. Transplantation Proceedings 19: 1896–1897, 1987

    PubMed  CAS  Google Scholar 

  • Noordzij T, Leunissen K, Van Hooff J. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation 52: 64–67, 1991

    PubMed  CAS  Google Scholar 

  • Nozue T, Kobayashi A, Kodama T, Uemasu F, Endoh H, et al. Clinical and laboratory observations: pathogenesis of cyclosporine-induced hypomagnesemia. Journal of Pediatrics 120: 638–640, 1992

    PubMed  CAS  Google Scholar 

  • Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Tufveson G, et al. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity in uremic patients. International Journal of Pharmacology 8: 1–11, 1986

    CAS  Google Scholar 

  • Ortho Multicenter Study Group. An randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New England Journal of Medicine 313: 337–342, 1985

    Google Scholar 

  • Paller M. The prostaglandin E analog misoprostol reverses acute cyclosporine nephrotoxicity. Transplantation Proceedings 20: 634–637, 1988

    PubMed  CAS  Google Scholar 

  • Pan WL, Chan CP, Huang CC, Lai MK. Cyclosporine induced gingival overgrowth. Transplantation Proceedings 24: 1393–1394, 1992

    PubMed  CAS  Google Scholar 

  • Patel JM. Metabolism and pumonary toxicity of cyclophosphamide. Pharmacology and Therapeutics 47: 137–146, 1990

    PubMed  CAS  Google Scholar 

  • Penn I. Cancer following cyclosporine therapy. Transplantation 43: 32–38, 1987

    PubMed  CAS  Google Scholar 

  • Perico N, Benigni A, Bosco E, Rossini M, Orisio S, et al. Acute cyclosporine-A toxicity in rats: Which role for renin angiotensin system and glomerular prostaglandins? Clinical Nephrology 25: S83–S88, 1986

    PubMed  CAS  Google Scholar 

  • Price GD, Olsen SL, Taylor DO, O’Connell JB, Bristow MR, et al. Corticosteroid-free maintenace immunosuppression after heart transplantation: feasibility and beneficial effects. Journal of Heart and Lung Transplantation 11: 403–414, 1992

    PubMed  CAS  Google Scholar 

  • Pritzker MR, Lake K, Reutzel T, Hoffman F, Jorgensen C, et al. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. Journal of Heart and Lung Transplantation 11: 415–420, 1992

    PubMed  CAS  Google Scholar 

  • Sanders CE, Curtis JJ, Julian BA, Gaston RS, Jones PA, et al. Tapering or discontinuing of cyclosporine for financial reasons: a single center experience. American Journal of Kidney Diseases 21: 9–15, 1993

    PubMed  CAS  Google Scholar 

  • Scherrer W, Vissing S, Morgan B, Rollins J, Tindall R, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. New England Journal of Medicine 323: 693–699, 1990

    PubMed  CAS  Google Scholar 

  • Schroeder TJ, First MR, Mansour ME, Hurtubise PE, Hariharan S, et al. Antimurine antibody formation following OKT3 therapy. Transplantation 49: 48–51, 1990

    PubMed  CAS  Google Scholar 

  • Shield C, Kahana L, Pirsch J, Vergne-Marini P, First MR, et al. Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 54: 164–165, 1992

    PubMed  Google Scholar 

  • Shield CF, Norman DJ, Marlett P, Fuccello AJ, Goldstein G. Comparison of antimouse and antihorse antibody production during the treatment of allograft rejection with OKT3 or antithymocyte globulin. Nephron 46 (Suppl. 1): 48–51, 1987

    PubMed  Google Scholar 

  • Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Canadian Medical Association Journal 147: 645–657, 1992

    PubMed  CAS  Google Scholar 

  • Small P, Hitcher M. Probable azathioprine hepatotoxicity: a case report. Annals of Allergy 62: 518–520, 1989

    PubMed  CAS  Google Scholar 

  • Smith SR, Creech EA, Schaffer AV, Martin LL, Rakhit A, et al. The effect of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney International 41: 199–205, 1992

    PubMed  CAS  Google Scholar 

  • Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Lerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation. Surgery, Gynecology and Obstetrics 124: 301–318, 1967

    PubMed  CAS  Google Scholar 

  • Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 14: 806–810, 1991

    PubMed  CAS  Google Scholar 

  • Stratta RJ, Armbrust MJ, Oh CS, Pirsch JD, Kalayoglu M. Withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 45: 323–328, 1988

    PubMed  CAS  Google Scholar 

  • Stuart F. Triple versus quadruple prophylaxis: summary of roundtable discussion. Transplantation Science 1: 4–8, 1991

    Google Scholar 

  • Suthanthiran M, Fotino M, Riggio RR, Chelgh JS, Stenzel KH. OKT-3 associated adverse reactions: mechanistic basis and therapeutic options. American Journal of Kidney Diseases 14 (Suppl. 2): 39–44, 1989

    PubMed  CAS  Google Scholar 

  • Tejani A, Ingulli E. Growth in children post-transplantation and methods to optimize post-transplant growth. Clinical Transplantation 5: 214–218, 1991

    Google Scholar 

  • Theil G, Harder F, Loetscher R, Loertscher R, Brunisholz M, et al. Cyclosporine alone or a combination with prednisone in cadaveric renal transplantation. Transplantation Proceedings 16: 1187–1189, 1984

    Google Scholar 

  • Thistlethwaite JR, Gaber AO, Haag BW, Aronson AJ, Broelsch CE, et al. OKT3 treatment of steroid-resistant allograft rejection. Transplantation 43: 176–184, 1987

    PubMed  Google Scholar 

  • Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, et al. Complications and monitoring of OKT3 therapy. American Journal of Kidney Diseases 11: 112–119, 1988

    PubMed  Google Scholar 

  • Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. New England Journal of Medicine 318: 48, 1988

    Google Scholar 

  • Tolkoff-Rubin NE, Rubin RH. Clinical approach to viral and fungal infections in the renal transplant patient. Seminars in Nephrology 36: 364–375, 1992

    Google Scholar 

  • Traeger J, Touraine JL, Fries D, Berthoux F. Evaluation of intravenous route for administration of antilymphocyte globulins in humans. Transplantation Proceedings 3: 749–753, 1971

    PubMed  CAS  Google Scholar 

  • Van Der Heide JJH, Bilo HJG, Tegzess AM, Domker AJM. The effects of dietary supplementation with fish oil on renal function in cyclosporine treated renal transplant recipients. Transplantation 49: 523–527, 1990

    Google Scholar 

  • Venkataseshan V, Feingold R, Dikman S, Churg J. Acute hyperuricemic nephropathy and renal failure after transplantation. Nephron 56: 317–321, 1990

    PubMed  CAS  Google Scholar 

  • Vincenti F, Vasconcelos M, Birnbaum J, Tomlanovich SJ, Amend WJ, et al. Pentoxifylline reduces the first dose reactions following OKT3. Transplantation Proceedings 25 (Suppl. 1): 57–59, 1993

    PubMed  CAS  Google Scholar 

  • Wagner K, Albrecht S, Neumanyer H-H. Prevention of post transplant acute tubular necrosis: a prospective randomized study. American Journal of Nephrology 7: 287–291, 1987

    PubMed  CAS  Google Scholar 

  • Wang JC, Gordon B, Cheigh JS, Riggio RR, Stenzel KH, et al. Use of granulocyte colony stimulating factor (G-CSF) in leu-kopenic renal transplant recipients. Abstract 106P. Journal of the American Society of Nephrology 3: 887, 1992

    Google Scholar 

  • Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. American Journal of Medicine 90: 32–36, 1991

    Google Scholar 

  • Weir MR, Klassen DK, Burdick JF. A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine-treated renal transplant recipients. Journal of the American Society of Nephrology 2: 1285–1290, 1992

    PubMed  CAS  Google Scholar 

  • Weir MR, Klassen DK, Shen SY, Sullivan D, Buddemeyer EU, et al. Adverse effects of intravenous cyclosporine on blood pressure, renal hemodynamics and urine prostaglandin production of healthy humans. Transplantation 49: 41–47, 1990

    PubMed  CAS  Google Scholar 

  • Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, et al. The role of T3/antigen receptor complex in T-cell activation. Annual Review of Immunology 17: 1807–1809, 1987

    Google Scholar 

  • Wilczek H, Ringden O, Tyden G. Cyclosporine associated central nervous system toxicity after renal transplantation. Transplantation 39: 110–115, 1985

    PubMed  CAS  Google Scholar 

  • Yamamoto H, Akazawa S, Yamaguchi Y, Yokota A, Yamasaki H, et al. Effects of cyclosporin A and low dosages of steroid on posttransplantation diabetes in kidney transplant recipients. Diabetes Care 14: 867–870, 1991

    PubMed  CAS  Google Scholar 

  • Yoshimura N, Oka T, Okamoto, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 53: 94–99, 1992

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Stephen J. Rossi

  2. Department of Internal Medicine, Division of Nephrology and Hypertension, University of Cincinnati Medical Center, 231 Bethesda Avenue, Cincinnati, Ohio, OH 45267-0585, USA

    Timothy J. Schroeder, Sundaram Hariharan &  M. Roy First

Authors
  1. Stephen J. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy J. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sundaram Hariharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Roy First
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossi, S.J., Schroeder, T.J., Hariharan, S. et al. Prevention and Management of the Adverse Effects Associated with Immunosuppressive Therapy. Drug-Safety 9, 104–131 (1993). https://doi.org/10.2165/00002018-199309020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199309020-00004

Keywords

Search

Navigation